

VIRAL HEPATITIS SITUATION AND RESPONSE IN **KIRIBATI**

2015



World Health
Organization
Western Pacific Region

VIRAL HEPATITIS SITUATION AND RESPONSE IN KIRIBATI

2015

© World Health Organization 2017

ISBN 978 92 9061 824 9

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition". Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

Suggested citation. Viral hepatitis situation and response in Kiribati 2015. World Health Organization Regional Office for the Western Pacific; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. 1. Hepatitis, Viral, Human – epidemiology, prevention and control. 2. Micronesia. I. World Health Organization Regional Office for the Western Pacific. (NLM Classification: WC 536)

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, Fax. No. (632) 521-1036, email: wpropuballstaff@who.int

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

For inquiries and request for WHO Western Pacific Regional Publications, please contact the Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, Fax. No. (632) 521-1036, email: wpropuballstaff@who.int

Photo credits

Cover: ©WHO/Yoshi Shimizu

CONTENTS

ABBREVIATIONS	iv
ACKNOWLEDGEMENTS	v
EXECUTIVE SUMMARY	vi
1. INTRODUCTION	1
1.1 Country background	1
1.2 Epidemiology	2
1.3 Health system structure	6
2. FINDINGS	9
2.1 Broad-based advocacy and awareness	9
2.2 Evidence-informed policy guiding comprehensive hepatitis action	10
2.3 Data supporting the hepatitis response	11
2.4 Stopping transmission	13
2.5 An accessible and effective treatment cascade	17
3. RECOMMENDATIONS	22
REFERENCES	25

ABBREVIATIONS

anti-HBs	hepatitis B surface antibody
anti-HBc	hepatitis B core antibody (Total)
APRI	aspartate aminotransferase-to-platelet ratio index
AST	aspartate aminotransferase
CI	95% Confidence interval
DHS	Demographic and Health Survey
EPI	Expanded Programme on Immunization
FBC	full blood count (haemoglobin, white blood cells and platelets)
HBcAb	hepatitis B core antibody
HBeAG	hepatitis B e-antigen
HBeAG	hepatitis B e-antigen
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HDV	hepatitis D virus
HDV RNA	hepatitis D RNA viral load
HIS	Health Information Service
KFHA	Kiribati Family Health Association
MSM	men who have sex with men
MTC	Marine Training Centre
NCD	noncommunicable disease
NMTC	National Medicines and Therapeutics Committee
PEN	WHO Package of Essential Noncommunicable Disease Interventions for Primary Health Care in Low-Resource Settings
STEPS	STEPwise approach to surveillance
STI	sexually transmitted infection
TCH	Tungaru Central Hospital
VCCT	voluntary confidential counselling and testing
VH	viral hepatitis
VIDRL	Victorian Infectious Diseases Reference Laboratory
WHO	World Health Organization

ACKNOWLEDGEMENTS

We thank the Kiribati Ministry of Health and Medical Services for supporting the work of the review team from the World Health Organization (WHO) Regional Office for the Western Pacific, which prepared this report. Akineti Nikuata, National Programme Officer, of WHO Kiribati coordinated the local meetings and visits, arranged a technical meeting on 26 August 2015 and assisted with compiling data for the report. We thank Andre Reiffer, the WHO Country Liaison Officer to Kiribati, for his guidance during the process and Eric Wiesen, former technical officer for hepatitis B immunization at the WHO Regional Office for the Western Pacific in 2015, for his identification of the need to move beyond immunization in Kiribati and making this review team mission possible.

The report was written by Julia Scott, consultant, and Nick Walsh, former Medical Officer (Viral Hepatitis), WHO Regional Office for the Western Pacific.

EXECUTIVE SUMMARY

A review of the viral hepatitis situation and response in Kiribati was carried out by a team from the World Health Organization (WHO) Regional Office for the Western Pacific in collaboration with the WHO Kiribati Country Liaison Office and the Kiribati Ministry of Health and Medical Services. The review took place from 24 August to 3 September 2015. The review team visited public hospitals, clinics and other services involved in viral hepatitis in South Tarawa and North Tarawa. The team reviewed infection control policies and practices in these settings, and met with health-care workers and community members. A technical meeting of key stakeholders was held on 26 August 2015 to discuss the burden of viral hepatitis and related liver disease, and strategies to achieve access to hepatitis B treatment in Kiribati.

Hepatitis B is highly endemic in Kiribati. Studies from past decades and recent laboratory data have indicated an adult prevalence of at least 15%. Hepatitis B immunization has resulted in a much lower childhood prevalence of hepatitis B surface antigen (HBsAg) at 3.3% among children 5–9 years old. However, this remains above the regional target. Hepatitis C prevalence in Kiribati is low, and as is incidence of hepatitis A and E and prevalence of hepatitis D, although data from the 1990s indicate that hepatitis D virus (HDV) is present. Transmission of hepatitis B has been predominantly mother-to-child and early horizontal, but other possible mechanisms for transmission exist, including sexual transmission and transmission in health-care settings.

There is low community awareness of hepatitis, and there is neither a specific national policy nor focal point for hepatitis. Data collection is very limited and the hepatitis treatment burden is unknown. There are limited data on cirrhosis and hepatocellular carcinoma. The hepatitis B infant immunization programme has shown success, though birth-dose coverage remains insufficient, and there have been limited catch-up vaccination initiatives to older groups. Policies for vaccinating close contacts of people with hepatitis B virus (HBV) and health-care workers do exist, though implementation is limited. Adult HBV vaccination is provided to some health-care workers and seafarers during vocational training. Infection prevention and control policies exist, but a lack of training and implementation have hampered the effectiveness of these policies.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26317

